Comparative Pharmacology
Head-to-head clinical analysis: HYRIMOZ versus SIMLANDI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYRIMOZ versus SIMLANDI.
HYRIMOZ vs SIMLANDI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HYRIMOZ (adalimumab-adbm) is a tumor necrosis factor (TNF) blocker. It binds to TNF-alpha and neutralizes its activity, thereby reducing inflammation and immune responses mediated by TNF.
SIMLANDI (adalimumab-adbm) is a tumor necrosis factor (TNF) blocker. It binds to TNF-alpha and inhibits its interaction with the p55 and p75 cell surface TNF receptors, thereby reducing inflammatory responses.
Subcutaneous injection: 40 mg every other week, or 80 mg every other week in patients with inadequate response. For induction in ulcerative colitis: 160 mg on day 1, 80 mg on day 15, then 40 mg every other week.
Subcutaneous injection, 40 mg every 2 weeks; may increase to 40 mg weekly if no response within 4 weeks.
None Documented
None Documented
11-17 days (mean ~14 days). The long half-life supports subcutaneous every-other-week dosing with potential dose interval adjustment in patients with high body weight or if trough levels are subtherapeutic.
Terminal elimination half-life is approximately 14 days (range 10–20 days) in patients with rheumatoid arthritis; this supports a subcutaneous dosing interval of every other week.
Predominantly catabolized to amino acids; renal excretion of metabolites and unchanged drug is negligible (<1%). Biliary/fecal excretion of intact antibody is minimal (<0.1%).
Adalimumab is eliminated primarily via catabolism to small peptides and amino acids; renal excretion of intact drug is negligible (<1%). Biliary/fecal excretion of intact drug is minimal.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor